Klotho Neurosciences Net Profit Margin 2023-2024 | KLTO

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

Klotho Neurosciences net profit margin from 2023 to 2024. Net profit margin can be defined as net Income as a portion of total sales revenue.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

Klotho Neurosciences net profit margin from 2023 to 2024. Net profit margin can be defined as net Income as a portion of total sales revenue.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$168.1B
Vertex Pharmaceuticals (VRTX)	$119.2B
Regeneron Pharmaceuticals (REGN)	$113.7B
Gilead Sciences (GILD)	$102.4B
Bristol Myers Squibb (BMY)	$101.3B
CSL (CSLLY)	$95.4B
GSK (GSK)	$84.1B
Alnylam Pharmaceuticals (ALNY)	$35B
Argenex SE (ARGX)	$32.8B
Biogen (BIIB)	$27.5B
BioNTech SE (BNTX)	$27.5B
Moderna (MRNA)	$24.5B
BeiGene (BGNE)	$20.1B
Illumina (ILMN)	$20.1B
Genmab (GMAB)	$15.8B
BioMarin Pharmaceutical (BMRN)	$13.1B
Vaxcyte (PCVX)	$12.7B
Exact Sciences (EXAS)	$12.5B
Insmed (INSM)	$12.5B
Incyte (INCY)	$12.2B
Bio-Techne Corp (TECH)	$11.9B
Sarepta Therapeutics (SRPT)	$11.9B
QIAGEN (QGEN)	$10.1B
Bio-Rad Laboratories (BIO.B)	$9.1B
Roivant Sciences (ROIV)	$8.7B
Ascendis Pharma (ASND)	$8.5B
Legend Biotech (LEGN)	$7.9B
Intra-Cellular Therapies (ITCI)	$7.9B
Repligen (RGEN)	$7.8B
Exelixis (EXEL)	$7.4B